Canada Post Corp Registered Pension Plan Purchases Shares of 1,215 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Canada Post Corp Registered Pension Plan purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,215 shares of the biopharmaceutical company's stock, valued at approximately $865,000.

A number of other hedge funds also recently made changes to their positions in REGN. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth $28,000. Rakuten Securities Inc. grew its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares during the last quarter. Avalon Trust Co acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $36,000. Crowley Wealth Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Private Wealth Management Group LLC increased its stake in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on REGN shares. Robert W. Baird lowered their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 5th. The Goldman Sachs Group decreased their price target on Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a report on Tuesday, February 4th. Finally, UBS Group downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $963.56.

Regeneron Pharmaceuticals Trading Up 2.5 %

Shares of NASDAQ:REGN traded up $13.88 during midday trading on Friday, reaching $563.16. The company's stock had a trading volume of 827,663 shares, compared to its average volume of 713,729. The firm has a 50 day moving average price of $645.94 and a two-hundred day moving average price of $736.51. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20. The firm has a market capitalization of $61.57 billion, a price-to-earnings ratio of 14.71, a PEG ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $11.86 EPS. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.